Clene Nanomedicine to Present at Upcoming Investor Conferences
Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on treating neurodegenerative diseases, announced its participation in several upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on treating neurodegenerative diseases, announced its participation in several upcoming healthcare conferences. Key events include the Roth 34th Annual Healthcare Conference on March 14, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, with respective presentation times of 3:00 PM ET and 8:40 AM ET. Webcasts will be available for on-demand viewing on the company's website. Clene aims to revolutionize treatments targeting energetic failure in neurological diseases.
Details
News Market Reaction – CLNN
The recorded move for CLNN in the trading session of this news was -3.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Clene will participate in the following upcoming conferences:
- Roth 34th Annual Healthcare Conference, March 14, 2022
Presentation Time: 3:00 pm ET
Webcast link: https://wsw.com/webcast/roth43/clnn/1822892
- Oppenheimer 32nd Annual Healthcare Conference, March 15, 2022
Presentation Time: 8:40 am ET
Webcast link: https://wsw.com/webcast/oppenheimer20/clnn/2765322
- Maxim Group Emerging Growth Conference, March 28, 2022
Presentation Time: 5:00 pm ET
Live audio webcasts will be available for on-demand viewing for the Roth and Oppenheimer Conferences and will be available on the Investors section of the company’s website at www.clene.com. A replay will be available after the events and archived on the website for 90 days.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Media Contact
Erica Fiorini, Ph.D., or David Schull
Russo Partners, LLC
Erica.fiorini@russopartnersllc.com
David.schull@russopartnersllc.com
+1-212-845-4253
Investor Contact
John Woolford
Managing Director, Westwicke
clene@westwicke.com
+1-443-213-0506
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.